Efficacy and tolerability of calcium channel alpha-2-delta ligands in psychiatric disorders

Vasiliu, O.; Vasile, D.; Mangalagiu, Andrei G.; Petrescu, Bogdan M.; Tudor, Corina; Ungureanu, D.; Cândea, C.

doi:10.55453/rjmm.2017.120.2.4

Cited by 7 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Self-perception is heavily correlated with body shape/weight ( 7 ). Antidepressants and cognitive-behavioral therapy (CBT) or interpersonal therapy are considered helpful for these patients ( 14 – 16 ). Fluoxetine is so far the only agent approved for the treatment of BN ( 17 ).…”

Section: Well-defined Eating Disorders-main Characteristicsmentioning

confidence: 99%

“…Program-based self-help interventions, CBT, and pharmacotherapy are available for BED, but the quality of evidence to support these interventions is very low ( 15 ). Pharmacological approaches are also explored but insufficiently validated by clinical, good-quality data ( 16 , 18 ). Lisdexamfetamine dimesylate is the only drug currently approved to treat BED ( 19 ).…”

Section: Well-defined Eating Disorders-main Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

An integrative model as a step toward increasing the awareness of eating disorders in the general population

Vasiliu¹

2023

Front. Psychiatry

Self Cite

View full text Add to dashboard Cite

Eating disorders (EDs) represent a contradictory chapter of clinical psychiatry, i.e., although they are associated with significant prevalence and risks in the long term (including vital risk, especially for anorexia nervosa), the therapeutic resources are minimal and based on low-quality data. Another contradiction arose in the last few decades, i.e., a variety of new EDs have been described, either by clinicians or signaled by mass media, but their systematic exploration is progressing very slowly. Entities like “food addiction,” “orthorexia nervosa,” or “emotional eating disorder” still require intensive exploration in order to find the most accurate diagnostic instruments, diagnosis criteria, prevalence data, vulnerability factors, and therapeutic approaches. This article is focused on integrating into a comprehensive model a variety of EDs not specified or loosely defined by the current international classifications of psychiatric disorders. This framework is intended as an instrument for stimulating clinical and epidemiological research, with potential favorable consequences for therapeutic research. The dimensional model suggested here includes four main categories that accommodate the already recognized EDs (i.e., anorexia nervosa, bulimia nervosa, and binge eating disorder) as well as ten EDs that still need intensive research to find their clinical and pathophysiological characteristics. More good-quality studies are urgently required regarding this topic, based on the mental and physical negative impact these EDs may have in the short and long term, especially in vulnerable populations (e.g., pregnant women, athletes, adolescents, etc.).

show abstract

Section: Well-defined Eating Disorders-main Characteristicsmentioning

confidence: 99%

Section: Well-defined Eating Disorders-main Characteristicsmentioning

confidence: 99%

An integrative model as a step toward increasing the awareness of eating disorders in the general population

Vasiliu¹

2023

Front. Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…According to the DSM-5-TR criteria, NES is included in the category of "Other specified feeding or eating disorder" [9]. This is considered progress in the way of achieving an independent nosological status for NES, because in the previous edition, DSM-IV-TR, this disorder was included in the category of "Eating disorders not otherwise specified" [90]. According to the DSM-5-TR, for diagnosing NES, the following criteria should be present: recurrent episodes of night eating (eating after awakening from sleep or excessive food ingestion after the evening meal), awareness preserved about the eating episodes, the recall of such episodes is possible, there are no external influences in the sleep-wake cycle or changes in local social norms, there is significant distress and/or impairment of functioning, and there is no other medical, substance-related, or psychiatric condition that may better explain these symptoms [9].…”

Section: Differential Diagnosismentioning

confidence: 99%

Current Evidence and Future Perspective in the Exploration of Sleep-Related Eating Disorder—From Pathogenic Hypotheses to Treatment Approaches

Vasiliu

2023

Preprint

View full text Add to dashboard Cite

Sleep-related eating disorder (SRED) is a non-REM parasomnia with potentially significant negative effects on general health (dangerous activities during night eating episodes, obesity, or metabolic syndrome, for example). Although the history of SRED encompasses more than six decades, public awareness and even the awareness of the mental health specialists of this disorder is very limited, a phenomenon that hinders the development of research in this field. Therefore, an updated review, based on a narrative methodology, explored the available evidence for SRED found in four electronic databases (PubMed, Cochrane Collaboration, Google Scholar, and Clarivate/Web of Science). A number of 94 primary and secondary reports were retrieved, investigating aspects regarding the risk factors, epidemiology, clinical data and differential diagnosis, epidemiology, structured evaluation, and treatment of SRED. Based on the results of these reports, Z-drugs, but also certain benzodiazepines, antidepressants, antipsychotics, and psychostimulants may trigger the onset of SRED. Psychiatric and neurologic disorders have also been associated with SRED, either as risk factors or comorbid conditions. Cerebral glucose metabolism dysfunctions, neurotransmitter dysfunctions, and genetic factors have been invoked as pathogenetic contributors. Structured assessment of SRED is possible, but there is a dearth of instruments dedicated to this purpose. Data on the prevalence and treatment of SRED exist, but good-quality epidemiological studies and clinical trials are still missing. In conclusion, future research is expected to address the shortcomings of SRED exploration by creating the conditions for better quality and larger group clinical research. The need for such investigation is granted by the importance of this pathology and its negative functional consequences.

show abstract

“…Gabapentinoids modulate α2δ of voltage-gated calcium channels and have been explored in numerous psychiatric disorders, MDD included (Vasiliu et al, 2017). A double-blind, randomized, crossover, placebo-controlled study compared the efficacy of gabapentin and lamotrigine monotherapy versus placebo in 31 patients with refractory unipolar or bipolar mood disorders who were monitored for 6 weeks (Frye et al, 2000).…”

Section: Other Agentsmentioning

confidence: 99%

Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents

Vasiliu¹

2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Many investigational drugs with antidepressant activity are currently explored in different phases of clinical research, with indications such as major depressive disorder, treatment-resistant major depression, bipolar depression, post-partum depression, and late-life depression. Although the vast majority of the antidepressants in clinical use are based on the monoaminergic hypothesis of depression, recent data supported the launching on the market of two new, non-monoamine-modulating drugs. Esketamine for treatment-resistant major depression and brexanolone for post-partum depression are two exceptions from the monoaminergic model, although their use is still limited by high costs, unique way of administration (only intravenously for brexanolone), physicians’ reluctance to prescribe new drugs, and patients’ reticence to use them. Glutamatergic neurotransmission is explored based on the positive results obtained by intranasal esketamine, with subanesthetic intravenous doses of ketamine, and D-cycloserine, traxoprodil, MK-0657, AXS-05, AVP-786, combinations of cycloserine and lurasidone, or dextromethorphan and quinidine, explored as therapeutic options for mono- or bipolar depression. Sestrin modulators, cholinergic receptor modulators, or onabotulinumtoxinA have also been investigated for potential antidepressant activity. In conclusion, there is hope for new treatments in uni- and bipolar depression, as it became clear, after almost 7 decades of monoamine-modulating antidepressants, that new pathogenetic pathways should be targeted to increase the response rate in this population.

show abstract

Efficacy and tolerability of calcium channel alpha-2-delta ligands in psychiatric disorders

Cited by 7 publications

References 0 publications

An integrative model as a step toward increasing the awareness of eating disorders in the general population

An integrative model as a step toward increasing the awareness of eating disorders in the general population

Current Evidence and Future Perspective in the Exploration of Sleep-Related Eating Disorder—From Pathogenic Hypotheses to Treatment Approaches

Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents

Contact Info

Product

Resources

About